Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.

about

Myasthenia gravis: the role of complement at the neuromuscular junction.Severe Infection of Pseudomonas aeruginosa during Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria.Risks of novel therapeutics: gonococcemia in an immune-suppressed patient receiving eculizumab.

P2860

Q47266287-2ADF594B-1272-4C41-BDBF-A2AAA4B3CDC6 Q49282674-BE3F27A9-8563-4D54-AEB7-65FF954DF037 Q49644876-6B72D35A-90DC-4495-8C1F-CDA4116AD767

P2860

Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.

Item

http://www.wikidata.org/entity/Q39554119

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Interim analysis of post-marke ...... urnal hemoglobinuria in Japan.

@en

Interim analysis of post-marke ...... urnal hemoglobinuria in Japan.

@nl

type

Item

label

Interim analysis of post-marke ...... urnal hemoglobinuria in Japan.

@en

Interim analysis of post-marke ...... urnal hemoglobinuria in Japan.

@nl

prefLabel

Interim analysis of post-marke ...... urnal hemoglobinuria in Japan.

@en

Interim analysis of post-marke ...... urnal hemoglobinuria in Japan.

@nl

P1476

Interim analysis of post-marke ...... urnal hemoglobinuria in Japan.

@en

P2093

Daisuke Harada

http://www.w3.org/2001/XMLSchema#string

Haruhiko Ninomiya

http://www.w3.org/2001/XMLSchema#string

Hideki Nakakuma

http://www.w3.org/2001/XMLSchema#string

Hirozumi Akiyama

http://www.w3.org/2001/XMLSchema#string

Itaru Matsumura

http://www.w3.org/2001/XMLSchema#string

Jun-Ichi Nishimura

http://www.w3.org/2001/XMLSchema#string

Kaichi Nishiwaki

http://www.w3.org/2001/XMLSchema#string

Keiya Ozawa

http://www.w3.org/2001/XMLSchema#string

Kensuke Usuki

http://www.w3.org/2001/XMLSchema#string

Kiyoshi Ando

http://www.w3.org/2001/XMLSchema#string

P2860

Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria

Diagnosis and management of paroxysmal nocturnal hemoglobinuria

Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria

FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria

The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry.

Natural history of paroxysmal nocturnal hemoglobinuria.

Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria.

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.

P2888

s12185-016-2065-4

P304

548-558

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12185-016-2065-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

Kazuma Ohyashiki

P577

2016-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27464489

http://www.w3.org/2001/XMLSchema#string

Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.

about

P2860

P2860

Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698